Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

This study is testing whether combining two anti-cancer drugs — anlotinib (a targeted therapy that cuts off a tumor's blood supply) and TQB2450 (an immunotherapy drug) — can help prevent esophageal squamous cell cancer from coming back after surgery. The treatment is given as a maintenance therapy after a successful operation. **You may be eligible if...** - You are 18 or older - You have confirmed esophageal squamous cell carcinoma that was fully removed with surgery (R0 resection) - Imaging shows no signs of cancer return 6-12 weeks after surgery - Your cancer was at an intermediate or advanced stage (T1-2 with lymph node involvement, or T3-4) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have received other anti-cancer treatments after your surgery - You have another active cancer (with minor exceptions) - Your cancer was in the uppermost part of the esophagus (cervical esophagus) - You have previously received targeted therapy or immunotherapy for esophageal cancer - You are allergic to the study drugs Talk to your doctor to see if this trial is right for you.